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ackground & Aims: Growth hormone (GH) and insulin-
ike growth factor-I (IGF-I) increase intestinal growth. GH
s thought to act indirectly via IGF-I. In several models,
ncluding rats given total parenteral nutrition (TPN), IGF-I
ore potently stimulates mucosal growth than GH, even
hen GH induces similar circulating IGF-I levels. These
tudies test the hypothesis that GH induces a suppressor
f cytokine signaling (SOCS), which inhibits intestinal
pithelial cell (IEC) proliferation. Methods: Rats on TPN
eceived vehicle, GH, or IGF-I. Jejunal SOCS (SOCS-1, -2,
3, and cytokine-inducible SH2-domain–containing pro-
ein [CIS]) and IGF-I messenger RNA (mRNA) were quan-
ified. Caco-2, IEC-6 cells, and SOCS-2 null and wild-type
WT) mice were used to examine the expression and
unctional role of SOCS-2. Results: As reported previ-
usly, IGF-I, but not GH, prevented mucosal atrophy
uring TPN, although GH elevated plasma IGF-I and
ncreased body weight. GH, but not IGF-I, induced jejunal
OCS-2 mRNA. SOCS-2 mRNA levels in GH and IGF-I-
reated rats inversely correlated with mucosal weight.
OCS-2 is expressed in Caco-2 cells, and elevated
OCS-2 expression in postconfluent cells is associated
ith reduced proliferative rates. SOCS-2 overexpression
n Caco-2 cells inhibited cell proliferation and promoted
ifferentiation. In IEC-6 cells, GH induced SOCS-2 and
educed basal or IGF-I–induced proliferation. GH also
educed proliferative activity in isolated crypts from WT
ut not SOCS-2 null mice, and SOCS-2 null crypts
howed enhanced proliferative responses to GH and
GF-I. SOCS-2 null mice have increased intestinal weight
nd length. Conclusions: SOCS-2 is a GH-inducible, novel
nhibitor of intestinal epithelial cell proliferation and
ntestinal growth.
rowth hormone (GH) and insulin-like growth fac-
tor (IGF)-I have both been shown to exert trophic
ctions on the intestinal epithelium.1–3 GH-induced in-
reases in circulating IGF-I have traditionally been
hought to mediate or contribute to GH action on in-estinal growth.3 Examination of the literature reveals,
owever, that the most potent trophic effects of GH on
ntestine have been observed in transgenic mice with
ong-term GH excess.2,3 Comparisons between GH and
GF-I transgenic mice1,2 and in models of systemic treat-
ent with GH or IGF-I indicate also that IGF-I has
uch more potent actions to increase crypt cell prolif-
ration than GH.1,2,4–9 This is somewhat surprising be-
ause, in these same models, GH elevates circulating
GF-I and promotes similar or greater increases in body
eight than IGF-I.1,2,4–7,9 These findings, together with
he fact that there is little evidence in the literature for
irect proliferative actions of GH on isolated epithelial
ells, have led us to hypothesize that GH may induce,
ithin the intestine, a factor that limits its stimulatory
ffects on crypt cell proliferation or those of IGF-I.
upport for the novel concept that GH may self-limit its
wn actions stems from recent observations that GH
nduces suppressors of cytokine signaling (SOCS), which
ct as negative feedback inhibitors of cytokine action.10
SOCS comprise a family of 8 related proteins: SOCS-1
hrough 7 and cytokine-inducible SH2-domain–con-
aining protein (CIS).10 A number of studies have shown
hat several SOCS family members can terminate or
nhibit GH activation of the Janus kinase–signal trans-
ucer and activator of transcription (STAT) path-
ay.11–15 An overgrowth phenotype of mice homozygous
or targeted disruption of SOCS-2 indicates a particular
Abbreviations used in this paper: CIS, cytokine-inducible SH2-do-
ain–containing protein; GAPDH, glyceraldehyde 3-phosphate dehy-
rogenase; GH, growth hormone; IEC, intestinal epithelial cell; IGF-I,
nsulin-like growth factor-I; RT-PCR, reverse-transcription polymerase
hain reaction; SOCS, suppressor of cytokine signaling; STAT, signal
ransducer and activator of transcription; TPN, total parenteral nutri-
ion; WT, wild-type.




































































































August 2004 SOCS-2 AND GH/IGF-I ACTION IN THE INTESTINE 571ole of SOCS-2 in limiting body growth and growth of
ome organs.16 The similarity in phenotype of SOCS-2
ull mice and mice overexpressing GH or IGF-I, as well
s increased hepatic expression of a number of GH-
nducible genes in liver of SOCS-2 null mice, suggests
hat SOCS-2 may have a key role in regulating GH or
GF-I action on growth in vivo. However, the role of
OCS-2 or other SOCS in GH or IGF-I action in the
ntestine is not yet defined, and there is no direct evi-
ence that SOCS-2 limits the mitogenic actions of GH or
GF-I. Although most current evidence suggests that
OCS interact with receptors for cytokines, which use
he Janus kinase–STAT pathway,10 yeast 2–hybrid data
uggest that SOCS-2 interacts with the type 1 IGF
eceptor, which is a receptor tyrosine kinase mediating
GF-I action.17 SOCS-2 is therefore an attractive candi-
ate as a GH-induced signaling molecule that could not
nly limit GH action but also could modulate IGF-I
ction or the interactions between GH and IGF-I in
egulating growth and proliferation of the intestinal
pithelium. The current studies first used a rat model of
otal parenteral nutrition (TPN), where differences in
otency of GH and IGF-I on intestinal growth have been
ell established.4,5,18 We used this model to test whether
H, but not IGF-I, induces SOCS-2 or other SOCS
amily members and whether this correlates with effects
f GH and IGF-I on mucosal mass. We then used model
ntestinal epithelial cell lines to examine more directly
hether SOCS-2 is expressed in intestinal epithelial cells
nd to examine its functional effects on cell proliferation
nd its regulation by GH. Isolated intestinal crypts from
OCS-2 null mice and wild-type (WT) littermates were
sed to test whether SOCS-2 deficiency alters the mito-
enic effects of GH or IGF-I on the intestinal epithe-




A rat TPN model was used to compare the effects of
H and IGF-I on jejunal SOCS expression and to test whether
hese effects correlate with effects on mucosal growth. The
PN model permits comparisons of GH and IGF-I action
nder conditions of identical nutrient intake.4 TPN experi-
ents were performed at the University of Wisconsin-Madison
nd approved by the Institutional Animal Care and Use Com-
ittee and have been described in detail elsewhere.19 Briefly,
50-g male Sprague Dawley rats (Harlan, Madison, WI) were
asted for 18 hours, anesthetized with 80 mg ketamine plus 8
g xylazine per kg body weight, and a catheter was inserted
nto the superior vena cava as previously described.4,19 The
nfusion of TPN solution was gradually increased from 30 mLn the day of surgery to 50 mL on day 1 and then 60 mL on
ays 2–7. During the last 6 days of TPN, animals were given
ntravenous GH or intravenous IGF-I (human recombinant
H or IGF-I, 800 g/day; Genentech, Inc., San Francisco,
A) or saline vehicle continuously coinfused with the TPN
olution. A group of rats allowed free access to food throughout
he experiment was studied in parallel with TPN groups to
rovide an orally fed control group. Body weight was moni-
ored throughout the experiment. After 8 days of exclusive
PN with 6 days of concomitant growth factor treatment,
nimals were anesthetized and blood was collected for radio-
mmunoassay of total plasma IGF-I as previously described.20
he abdomen was opened by midline incision and jejunum
as dissected and flushed with ice-cold saline. Corresponding
ejunal segments were collected for assay of mucosal dry mass
mg/cm) or RNA extraction as previously described.4,5 Colon
as also collected for RNA extraction.
RNA Extraction and Northern Blot Analysis
Total RNA was isolated from jejunum and colon, and
bundance of SOCS-1, -2, -3, and CIS messenger RNAs
mRNAs) was assayed by Northern blot hybridization using
32P]-labeled antisense complementary RNA or complemen-
ary DNA probes and methods detailed previously.21 Mouse
OCS-1, -2, -3, and CIS probes were provided by Dr. Douglas
ilton (Walter and Eliza Hall Institute, Melbourne, Austra-
ia).22 Abundance of the constitutively expressed ribosomal
rotein PL-7 mRNA was used as a control for RNA loading.
GF-I mRNA was assayed in jejunum by ribonuclease protec-
ion assay using rat IGF-I and glyceraldehyde 3-phosphate
ehydrogenase (GAPDH) (control) (Ambion, Austin, TX)
omplementary RNA probes as previously described.23
In Vitro Analyses
Caco-2 and intestinal epithelial cell (IEC)-6 cells were
btained from the American Type Culture Collection (Rock-
ille, MD) and were used to examine the proliferative effects of
H, expression of SOCS-2 in intestinal epithelial cells, and
unctional effects of SOCS-2 on proliferation. Caco-2 cells are
ne of the few intestinal epithelial cell lines reported to be GH
esponsive,24,25 and, although derived from a colon cancer,
aco-2 cells exhibit characteristics of small intestinal entero-
ytes in their ability to differentiate spontaneously and express
ucrase-isomaltase and alkaline phosphatase. In addition, the
ates of spontaneous proliferation of Caco-2 cells in serum-free
r serum-containing media are known to depend largely on
utocrine or serum-derived IGFs, respectively.8,26 IEC-6 cells
ere used as an independent, nontransformed cell line that has
ot previously been tested for GH responsiveness but shows a
obust proliferative response to IGF-I.27 Both cell lines were
ropagated in Dulbecco modified Eagle’s medium (Gibco
RL, Grand Island, NY) supplemented with 10% fetal bovine
erum, 50 U/mL penicillin, 50 g/mL streptomycin, and 10
mol/L HEPES (growth medium).
For assays of GH or IGF-I action on proliferation, cells were































































































572 MILLER ET AL. GASTROENTEROLOGY Vol. 127, No. 2ransferrin and 0.1% bovine serum albumin (Sigma, St. Louis,
O) or 5 g/mL selenous acid (Sigma).28 [3H]-thymidine
ncorporation was measured as previously described.27,29 To
tudy SOCS-2 expression, total RNA was isolated by using
RIzol reagent according to manufacturer’s instructions (Gibco
RL). Assays of SOCS-2 mRNA in Caco-2 cells were performed
s described above but used a human SOCS-2 probe provided by
r. Richard Furlanetto (Juvenile Diabetes Research Foundation,
ew York, NY)17 and a human GAPDH probe (Ambion) as a
oading control. SOCS-2 and control GAPDH mRNA were
easured in IEC-6 cells by reverse-transcription polymerase chain
eaction (RT-PCR), using standard amplification conditions.30
ligomers used for RT-PCR were hSOCS-2 sense (5GTG-
GTGACAGTGTCTGCGAGAGAC3), hSOCS-2 antisense
5GTCCCCGGATGGTACCGGTACACTT3), GAPDH sense
5CTACTGGCGCTGCCAAGGCTGT3), and GAPDH anti-
ense (5GCCATGAGGTCCACCACCCTGTTG3).
The functional effects of SOCS-2 over expression were stud-
ed in Caco-2 cells. Caco-2 cells were transfected with a human
BIG2i-FLAGSOCS-2 expression vector or empty vector pro-
ided by Dr. Furlanetto.17,31 pBIG2i-FLAGSOCS-2 contains
he complete coding sequence of human SOCS-2 with a FLAG
pitope tag downstream from the repressed tetracycline trans-
ctivator (rtTAN), tetracycline/doxycycline-inducible pro-
oter, and a hygromycin resistance gene to permit selection of
ransfected cells. The empty vector is identical except that it
acks the inserted SOCS-2 coding sequence.17,31 Cells were
eeded in growth medium at 60%–80% confluence. After 24
ours, medium was switched to growth medium plus endo-
oxin-free plasmid and Effectene as per manufacturer’s instruc-
ions (Qiagen Inc., Valencia, CA). Twenty-four hours after
ransfection, medium was changed to remove Effectene and
etached cells. The remaining cells were switched to growth
edium plus hygromycin (100 g/mL) to maintain selection
f transfected cells and doxycycline (1 g/mL) to maximize
OCS-2 expression. Dependent on the experiment, functional
nalyses were performed between 24 hours and 15 days after
nitial selection with hygromycin, during which time fresh
rowth medium plus hygromycin and doxycycline were added
very 48 hours to maintain selection of transfected cells and
aximal expression of transfected plasmid. Northern hybrid-
zation for SOCS-2 mRNA and immunoprecipitation of
pitope tagged SOCS-2 with an M2 Anti-FLAG antibody
Sigma Diagnostic Inc., St. Louis, MO) followed by western
mmunoblot with the same anti-FLAG antibody were used to
erify over expression of SOCS-2.
Assays of Differentiation Markers in Caco-2
Cells
Sucrase-isomaltase mRNA was quantified by northern
ybridization using a sucrase-isomaltase complementary RNA
nd GAPDH as control. Alkaline phosphatase activity was
ssayed using a kit from Sigma Diagnostic Inc. (St. Louis, MO)
ollowing manufacturer’s instructions.In Vivo Analyses: SOCS-2 Null and WT Mice
SOCS-2 null mice were derived as previously de-
cribed.16 Heterozygote male and female mice were bred to
rovide age-matched SOCS-2 null and WT mice for analyses.
dult (100–200-day-old) mice were anesthetized, and the
ntire small intestine from pylorus to ileocecal valve and colon
as dissected. Length and weight of the entire small intestine
nd colon were recorded. To assess whether absolute SOCS-2
eficiency altered crypt proliferation, isolated colonic crypts
ere prepared by using a modified method described by
hitehead et al.32 and tested for responses to GH, IGF-I, and
H plus IGF-I by using [3H]-thymidine incorporation into
NA as a readout. The lumen of dissected colon was washed
equentially in ice-cold phosphate-buffered saline (pH 7.4)
lus 1.5 mmol/L dithiothreitol, then phosphate-buffered sa-
ine  27 mmol/L Na citrate at room temperature. The colon
as then incubated/washed at room temperature in 20 mL of
rypt elution buffer (phosphate-buffered saline containing 3
mol/L EDTA and 0.5 mmol/L dithiothreitol, 50 U/mL
enicillin, and 50 g/mL streptomycin). Every 15 minutes,
he colon was first shaken gently and allowed to settle, and
upernatants were removed and visualized under an inverted
icroscope. The first washes remove debris within the super-
atants, and supernatants collected at 45–90 minutes con-
ained intact crypts. Crypts were pooled into Dulbecco mod-
fied Eagle’s medium plus antibiotics. Pooled crypts were
ently centrifuged (200g) for 5 minutes. Supernatants were
spirated and pelleted crypts resuspended in Dulbecco modi-
ed Eagle’s medium and counted by using a hemocytometer.
qual numbers of crypts from WT and SOCS-2 null mice were
eeded into 24-well plates precoated with purified collagen
Vitrogen 100, 2.9 mg/mL; Celtrix Pharmaceuticals, Santa
lara, CA). After 60-minute incubation in serum-free me-
ium, fresh medium was added with [3H]-thymidine (2 Ci/
L) plus or minus GH (109 mol/L), IGF-I (10 ng/mL), or
H and IGF-I in combination. Acid-precipitated DNA was
arvested in 0.2 N sodium hydroxide, 0.1% sodium dodecyl
ulfate, and counted as for cultured cells. Data were expressed
s fold stimulation by treatments relative to serum-free con-
rol.
Statistical Analyses
Values are expressed as mean  SEM. One-way anal-
sis of variance followed by Fisher protected least significant
ifferences multiple t test was used to test for differences
etween groups.
Results
Effects of GH and IGF-I in TPN-Fed Rats
Body weight, plasma IGF-I, and mucosal mass
ata for some of the treatment groups have been reported
reviously for the animals used in this study.19 These
rior data are shown in Table 1 to show key points



































































August 2004 SOCS-2 AND GH/IGF-I ACTION IN THE INTESTINE 573etween mass of jejunal mucosa and jejunal SOCS-2
RNA. As reported previously in these animals19 and
revious studies with similar experimental design,4,5
PN-fed rats showed reductions in body weight gain,
lasma IGF-I, and mass of jejunal mucosa relative to
rally fed animals (Table 1). Administration of IGF-I to
PN-fed rats restored body weight gain, plasma IGF-I,
nd mucosal mass toward values observed in orally fed
ontrols. In contrast, administration of GH restored body
eight gain and plasma IGF-I but not the mass of jejunal
ucosa (Table 1). Levels of plasma IGF-I achieved in
PN-fed rats given GH were not as high as in IGF-I-
nfused rats. It is important to note, however, that body
eight gain achieved in GH- and IGF-I–infused rats was
dentical. In previous, similarly designed studies, even
hen plasma IGF-I levels did not differ significantly
etween GH- and IGF-I–treated TPN-fed rats, GH still
id not increase jejunal mucosal mass, despite similar
fficacy as IGF-I in restoring body weight gain.4,5 Jejunal
ucosal IGF-I mRNA was assayed in the present study,
nd, consistent with previous findings,33 there was a
onsignificant trend for reduced IGF-I mRNA in TPN-
ed rats relative to orally fed rats, and neither GH nor
GF-I significantly affected jejunal IGF-I mRNA
Table 1).
Effects of GH and IGF-I on SOCS mRNA in
TPN-Fed Rats
SOCS-2 and CIS mRNA were expressed at low
evels in the intestine of orally fed or TPN-fed rats, and
here was no significant effect of TPN itself on the
bundance of SOCS-2 or CIS mRNA (Figure 1). SOCS-2
RNA was significantly induced in the jejunum by GH
ut not by IGF-I (Figure 1). Regression analysis in the
H and IGF-I treated groups showed an inverse corre-
ation (R  0.63; P  0.05) between SOCS-2 mRNA
nd mucosal mass, indicating a significant association
etween high level SOCS-2 expression in GH-treated
ats and the lack of observed enterotrophic action of GH.
IS expression was more variable than SOCS-2 and was





ral 40  3b 7.9 
PN 12  3 3.9 
PN  GH 34  1b 4.1 
PN  IGF-I 31  3b 7.7 
OTE. Values are means  SE. n  5/group.
IGF-I mRNA abundance normalized to GAPDH control mRNA.
P  0.01 vs. TPN control.
P  0.01 vs. TPN  GH.ot significantly affected by TPN or TPN plus GH or
GF-I infusion (Figure 1). SOCS-1 and SOCS-3 mRNA
ere expressed at barely detectable levels in the jejunum
f TPN-fed rats, and, as shown in Figure 1A, these
RNA were not discernibly induced by GH or IGF-I.
ecently, we have found that, in colon, as in jejunum,
GF-I, but not GH, significantly increased crypt depth
E. Dahly, Ph.D. thesis) in TPN-fed rats. We therefore
ssessed SOCS-2 expression in colon and found that GH
ncreased SOCS-2 mRNA 2.2  0.75-fold relative to
PN alone (P  0.05), whereas IGF-I was without effect
1.0  0.33-fold relative to TPN, P  0.98). We
ttempted to localize the sites of SOCS-2 mRNA expres-
ion by in situ hybridization histochemistry, but this
ielded signals that were not conclusively different from
F-I, and Jejunal IGF-I mRNA Abundance




b 377  14b 4.3  2.6
304  9 2.0  0.6
435  15b 3.4  2.2
b,c 694  21b,c 2.7  0.8
igure 1. Jejunal SOCS mRNA expression in rats on TPN given GH,
GF-I, or saline vehicle (Sal). (A) Representative autoradiograms of
orthern blots probed for SOCS-1, SOCS-2, SOCS-3, CIS, and PL-7
ontrol mRNAs. (B) Histograms of SOCS-2 or CIS mRNA normalized to











































































574 MILLER ET AL. GASTROENTEROLOGY Vol. 127, No. 2ackground, even when probes were double labeled with
35S]-UTP and [35S]-CTP to increase sensitivity (data not
hown). Immunohistochemistry with available SOCS-2
ntibodies also did not detect SOCS-2 protein. We at-
ribute this to the low abundance of SOCS-2 mRNA and
rotein and note that there is currently, to our knowl-
dge, only 1 article localizing SOCS-2 mRNA, and this
as performed in developing brain.34 We could find no
eport on cellular localization of SOCS-2 protein in any
issue in vivo, suggesting that suitable antibodies and/or
ufficiently sensitive methods are yet to be developed.
e therefore turned to in vitro systems to test specifi-
ally whether SOCS-2 is expressed in intestinal epithelial
ells and to examine its functional effects on cell prolif-
ration.
SOCS-2 Is Expressed in Intestinal Epithelial
Cells and SOCS-2 Expression Is Increased
in Postconfluent Cells
We first characterized endogenous SOCS-2 ex-
ression in Caco-2 cells, which show a characteristic log
hase proliferation when subconfluent, followed by
lower rates of proliferation postconfluence.8,26 As shown
n Figure 2, SOCS-2 is expressed in Caco-2 cells but at
ow abundance in subconfluent cells (2–5 days after
lating) and at significantly higher levels in confluent
nd postconfluent cells (10–15 days after plating), which
how reduced proliferative rates (Figure 2).
SOCS-2 Overexpression in Caco-2 Cells
Reduces Proliferation and Promotes
Differentiation
Transfection-mediated SOCS-2 over expression
as used to test directly whether SOCS-2 inhibits
roliferation of Caco-2 cells. We initially identified
onditions that minimized endogenous SOCS-2 ex-
ression to avoid complications because of the ob-
erved density-dependent changes in endogenous
OCS-2. As shown in Figure 3A, endogenous SOCS-2
RNA was significantly down-regulated in cells
rown in medium plus serum compared with serum-
ree medium. In subsequent experiments to test the
unctional effects of SOCS-2, cells were maintained in
erum after transfection to minimize endogenous
OCS-2 and switched to serum-free medium 4 –16
ours before experiments. We also verified that trans-
ection, followed by incubation in serum-containing
edium plus hygromycin to select transfected cells
nd doxycycline to induce expression of transfected
lasmid, yielded overexpression of SOCS-2 mRNA
nd FLAG-epitope-tagged SOCS-2 protein in cellsransfected with SOCS-2 expression vector compared
ith empty vector (Figure 3B).
DNA synthesis and cell morphology were monitored
n Caco-2 cells transfected with empty vector or SOCS-2
xpression vector over 4–13 days after plating. As re-
orted in the literature for Caco-2 cells,8,26 empty vector
ransfected cells showed a typical log phase growth from
ays 4 to 8, when cells were at low density, and then
lateau phase growth at higher densities (Figure 4A ).
OCS-2 transfected cells showed similar levels of DNA
ynthesis at 4 days after plating (immediately after the
nitial hygromycin selection of transfectants), but, by day
, DNA synthesis was significantly reduced relative to
mpty vector transfected cells. After this time point,
OCS-2-transfected cells failed to exhibit the typical log
hase growth and showed earlier plateau phase growth
han empty vector transfected cells. Morphologic exam-
nation verified similar numbers of surviving empty vec-
or or SOCS-2 transfectants at day 4, immediately after
nitial hygromycin selection, but, by day 13, empty
igure 2. Density-dependent changes in expression of SOCS-2 in
aco-2 cells. Autoradiograms are of SOCS-2 and control GAPDH mR-
As in subconfluent (2–5 days after plating) and confluent (10–15
ays after plating) Caco-2 cells grown in serum-free medium. Histo-
rams are of SOCS-2 mRNA abundance normalized to control GAPDH
RNA. Data are means  SEM (n  5 or 6 at each time point; a 


























































August 2004 SOCS-2 AND GH/IGF-I ACTION IN THE INTESTINE 575ector transfected cells formed larger colonies than
OCS-2-transfected cells (Figure 4B). Detached or dead
ells per plate were collected and counted daily over the
ntire study period and did not differ significantly in
mpty vector transfected cells (2750  281) and SOCS-2
ransfected cells (3237  314, P  0.27). Thus, SOCS-2
verexpression appeared to reduce cell proliferation
ather than cell survival. SOCS-2–transfected cells
howed increased expression of sucrase-isomaltase
RNA and elevated alkaline phosphatase activity (Fig-
re 5), indicating that, in addition to exerting antipro-
iferative actions, SOCS-2 overexpression promotes dif-
erentiated phenotype.
Caco-2 cells did not prove useful to study whether
OCS-2 alters the mitogenic actions of GH or IGF-I be-
ause the cells proved unresponsive to exogenous GH or
GF-I. We attribute this to their documented high-level
ecretion of IGF-II, which exerts autocrine mitogenic effects
ia the same type 1 IGF receptor as IGF-I.8,26 We therefore
urned to IEC-6 cells and isolated crypts from SOCS-2 null
nd WT mice as alternate systems.
igure 3. SOCS-2 expression in Caco-2 cells grown in serum or
erum-free medium or after transfection with SOCS-2 vector. (A)
OCS-2 mRNA abundance in subconfluent Caco-2 cells grown in
edium with or without serum (serum-free). Autoradiograms show
epresentative examples of cells at 10 days after plating. Histograms
how mean SOCS-2 mRNA abundance normalized to control GAPDH
RNA in cells cultured for 5–10 days in serum-free or serum-contain-
ng medium (n  3 per group; a  P  0.05 in cells grown in
erum-free vs. serum-containing medium). (B) Increased SOCS-2
RNA and protein in Caco-2 cells transfected with SOCS-2 (S-2)
xpression vector vs. empty vector (E). Autoradiograms show SOCS-2
RNA (top) and SOCS-2 protein (immunoprecipitated with antibody to
he FLAG epitope) in cells at 5 days after transfection. Histograms
how mean SOCS-2 mRNA abundance at 5–10 days after transfection.GH Inhibits Spontaneous or IGF-I–Induced
Proliferation of IEC-6 Cells and Induces
SOCS-2
We examined GH action in IEC-6 cells as an
ndependent measure of the direct proliferative actions of
H in a nontransformed intestinal epithelial cell line. As
hown in Figure 6A, GH reduced basal DNA synthesis
n IEC-6 cells. RT-PCR showed that levels of SOCS-2
RNA were very low in untreated cells but were in-
uced by GH (Figure 6B). Because IEC-6 cells show
obust proliferative responses to IGF-I, we tested
hether coincubation with GH affected this response. As
hown in Figure 7, IGF-I alone potently stimulated
igure 4. Effects of SOCS-2 overexpression on basal proliferation in
erum. (A) Growth curves in SOCS-2 vector transfected vs. empty
ector transfected Caco-2 cells at different times after transfection.
ine graph shows cell proliferation (means  SEM) measured as
ncorporation of [3H]-thymidine into DNA (n  4 per time point). Cells
ere maintained in serum up to the 24 hours prior to study and
witched to serum-free medium plus thymidine for 24 hours. SOCS-2
ransfected cells showed significantly lower DNA synthesis (P  0.05)
t each time point assessed except day 4. (B) Morphology of Caco-2
ells transfected with SOCS-2 vector or empty vector. Phase-contrast
ictures of Caco-2 cells transiently transfected with SOCS-2 vector or
mpty vector control taken at day 4 and day 13. Note the similar
umbers of cells at day 4 and the smaller colonies in SOCS-2 trans-























































576 MILLER ET AL. GASTROENTEROLOGY Vol. 127, No. 2NA synthesis in IEC-6 cells, but this effect was atten-
ated by coincubation with GH. The attenuation of basal
nd IGF-I–induced DNA synthesis in IEC-6 cells by
H, coincident with induction of SOCS-2, supports our
ypothesis that SOCS-2 serves as a GH-inducible factor,
hich limits the mitogenic actions of GH or IGF-I in
ntestinal epithelial cells.
SOCS-2 Deficiency Increases
Responsiveness of Isolated Crypts to GH
and IGF-I and Promotes Increased
Intestinal Growth
Attempts to manipulate SOCS-2 expression in
EC-6 cells by transfection-based approaches proved
roblematic because transfection even with an empty
ector transformed the cells, making them unrespon-
ive to IGF-I. Isolated crypts from SOCS-2 null and
T mice were therefore used to test whether the
ntiproliferative effects of GH observed in IEC-6 cells
ccurred in normal intestinal epithelium and whether
OCS-2 is required for this effect. As in IEC-6 cells,
H reduced DNA synthesis in WT crypts, and this
ffect was abolished in crypts from SOCS-2 null mice
Figure 8A ). IGF-I alone did not significantly affect
NA synthesis in WT crypts but tended to increase
NA synthesis in SOCS-2 null crypts. GH and IGF-I
n combination significantly increased DNA synthesis
n crypts from SOCS-2 null but not WT mice, and the
igure 5. SOCS-2 overexpression promotes Caco-2 cell differentia-
ion. (A) Autoradiograms of sucrase-isomaltase mRNA in Caco-2 cells
ransfected with empty vector (E) or SOCS-2 expression plasmid (S-2).
istograms show means  SEM of sucrase mRNA abundance (a 
 0.05 vs. empty vector control at day 7 after transfection). (B)
hows alkaline phosphatase activity in SOCS-2 vs. empty vector
ransfected cells. Histograms represent means  SEM at day 7 after
ransfection.esponse to GH plus IGF-I in SOCS-2 null crypts was
ignificantly greater than the response to GH alone
Figure 8A ). These findings directly support the con-
ept that SOCS-2 limits the proliferative effects of GH
r GH in combination with IGF-I in the intestinal
pithelium. Increased weight and length of the small
ntestine and colon in SOCS-2 null mice relative to
ge-matched WT littermates (Figure 9) also show that
OCS-2 limits intestinal growth in vivo. Increases in
eight (41.1%  8.3% colon, 27.6%  3.9% small
ntestine) but not length (19.9%  2.8% colon,
2.7%  1.1% small intestine) were comparable with
ncreases in body weight (30.1%  3.2%).
igure 6. GH inhibits DNA synthesis in IEC-6 cells and induces
OCS-2. (A) Histograms show [3H]-thymidine incorporation into DNA
n subconfluent IEC-6 cells grown on 24-well plates in serum-free
edium alone or plus GH (2  108 mol/L) for 24 hours. Values are
eans  SEM (n  4 per group; a  P  0.05 vs. serum-free control).
ata were replicated in 2 independent experiments. (B) RT-PCR of
OCS-2 and GAPDH mRNA in serum-free or GH-treated IEC-6 cells.
epresentative gel is shown at left after 24-hour GH treatment. Right
hows histograms of mean SOCS-2 mRNA abundance normalized to
ontrol GAPDH mRNA (n  4; a  P  0.05 vs. serum-free controls,
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Although trophic actions of GH on the intestine
ave been noted in animal models of chronic GH excess2
r with GH treatment of GH-deficient animals,35,36 GH
oes not prevent or reverse the atrophy of the intestinal
ucosa associated with restriction of oral nutrient and
PN in rats.4 This is despite the fact that GH treatment
ncreases circulating IGF-I and causes similar increases in
ody weight as observed with IGF-I treatment, which
oes potently stimulate mucosal growth and crypt cell
roliferation in the TPN model.4 The differential respon-
iveness of the intestinal mucosa to GH and IGF-I dur-
ng TPN was confirmed in the present study and was
hown to correlate with induction of SOCS-2 in the
ntestine by GH and not IGF-I. These findings support
hypothesis that, during TPN, SOCS-2 limits the ac-
ions of GH and/or GH-induced circulating IGF-I on
ntestinal epithelial cell proliferation and mucosal
rowth. In other tissues such as liver, GH has been
hown to induce CIS, SOCS-1, and SOCS-3 as well as
OCS-2.22,37,38 Our study provides new evidence that, in
ntestine, SOCS-2 is specifically or preferentially induced
y GH. We cannot exclude the possibility that other
OCS are induced in intestine at other times after GH,
lthough preliminary analyses at earlier time points in-
igure 7. GH attenuates spontaneous and IGF-I–mediated prolifera-
ion of IEC-6 cells. DNA synthesis in cells treated with IGF-I (10 ng/mL)
r GH (2  108 mol/L) alone or in combination for 24 hours.
istograms show means  SEM of [3H]-thymidine incorporation into
NA expressed as fold-stimulation relative to serum-free control (n 
, a  P  0.05 vs. no treatment control; b  P  0.05 vs. GH or IGF-I
lone).icate that GH induces SOCS-2 but has no effect on CIS,
OCS-1, or SOCS-3.39
Although we have used the TPN model to compare
H and IGF-I action, we note that a majority of studies
esting GH in other models, including orally fed ro-
ents40,41 and resection models,7,9,42 report that GH has
ittle or no effect on crypt proliferation, despite increas-
ng body weight and plasma IGF-I. One study of 90%
mall bowel resection and very high-dose GH43 and
nother of 70% resection, TPN, and intermediate-dose
H report positive effects on crypt proliferation.44 It
ould be of interest to establish whether variable growth
esponses in these models correlate with SOCS-2 expres-
ion. Studies of GH in humans with short-bowel syn-
rome also indicate anabolic effects,45–47 but variable
igure 8. Mitogenic effects of GH and IGF-I in isolated crypts from WT
nd SOCS-2 null mice. (A) Shows representative photomicrographs of
solated crypts. (B) Shows [3H]-thymidine incorporation (means 
EM) in WT and SOCS-2 null (S2-N) crypts treated with IGF-I, GH, or
GF-I plus GH (a  P  0.05 vs. no treatment, b  P  0.05 vs. WT,













































































578 MILLER ET AL. GASTROENTEROLOGY Vol. 127, No. 2ffects on intestinal growth or nutrient uptake have been
eported.48–50 The variable responses may reflect dose of
H or coadministered nutritional interventions. How-
ver, our current studies suggest that SOCS-2 may play
critical role in the outcome of GH treatment. Evalua-
ion of SOCS expression in intestine in other rodent
odels and in GH-treated patients would therefore be of
ignificant future interest. Crypt proliferation was in-
uced in GH transgenic mice vs. WT during recovery
rom colitis induced by dextran sulfate,51 although crypt
roliferation is not increased in untreated GH transgen-
cs.2 This points to distinct mechanisms of action of GH
n normal and inflamed intestine.
It is well established that IGF-I stimulates prolifera-
ion of multiple cell lines derived from the intestinal
pithelium (reviewed in Lund3), but such information for
H is scarce. One study reported proliferative actions of
H in Caco-224 cells, but we could not replicate this
bservation in the current studies. Cells in culture com-
only lose GH responsiveness, especially with increasing
assage number.3 Although the reasons for this are un-
nown, our inability to replicate the previously observed
ffects of GH in Caco-2 cells, even when utilizing similar
igure 9. SOCS-2 deficiency increases length and weight of the small
ntestine and colon. Histograms show mean weight and length of
ntire small intestine and colon for SOCS-2 null mice and age- and
ex-matched WT mice (n  6, a  P  0.05 vs. WT).ulture conditions, may reflect increasing passage num-
er of available Caco-2 cells. Another report in confluent,
ifferentiated T84 colon cancer cells indicates respon-
iveness to GH in terms of regulation of chloride secre-
ion and is consistent with the ability of GH to regulate
ome aspects of differentiated enterocyte function in
ivo.4 Although the focus of this study was on trophic
ctions of GH, the T84 cell line may prove useful for
uture studies of the relationship between SOCS-2 and
H action on differentiation in intestinal epithelial cells.
n the nontransformed IEC-6 cell line and in isolated
rypts from WT animals, GH exerts antiproliferative
ctions. GH unresponsive Caco-2 cells spontaneously
xpress SOCS-2, GH induces SOCS-2 in IEC-6 cells, and
OCS-2 deficiency abrogates the antiproliferative effects
f GH in isolated crypts. This, together with findings
hat SOCS-2 overexpression in Caco-2 cells limits spon-
aneous proliferation, provides strong evidence that
OCS-2 limits proliferation of intestinal epithelial cells
nd that SOCS-2 mediates or contributes to the less
otent mitogenic effect of GH than IGF-I. Inhibitory
ffects of GH on proliferation of IEC-6 cells and isolated
rypts counter the traditionally held view of GH as a
rowth-promoting hormone. However, it is important to
ote that, in other systems, GH has been shown to
ntagonize the actions of the insulin receptor, which is
tructurally related to the type 1 IGF receptor,52 and this
ffect has recently been linked to SOCS-1.53 The concept
hat GH may restrain IGF-I action or attenuate the
uration or magnitude of IGF-I action is fundamentally
mportant to delineating the relative roles GH vs. IGF-I
n growth of intestine and other organs. Observations
hat GH induces SOCS-2 in colon of TPN-fed animals,
s well as small intestine, and that SOCS-2 inhibited
roliferation of Caco-2 colon cancer cells indicates that
dditional studies of the possible role of SOCS-2 in
olorectal cancer or the effects of the GH–IGF-I axis on
olorectal cancer54 are warranted. In this regard, it is of
nterest that recent studies show that SOCS-2 expression
s down-regulated in pulmonary adenocarcinoma.55
SOCS generally serve as feedback inhibitors, which
imit the duration or magnitude of cytokine or growth
actor action rather than preventing their biologic ef-
ects.10 In this regard, we propose that SOCS-2 attenu-
tes the magnitude or duration of crypt cell proliferation
nd mucosal growth in response to GH or GH-induced
GF-I rather than completely preventing IGF-I action. In
he IEC-6 cells, GH coincubation attenuated but did not
revent IGF-I action on IEC-6 cells. The intestine is not
otally unresponsive to GH during TPN. In the same





























































































August 2004 SOCS-2 AND GH/IGF-I ACTION IN THE INTESTINE 579ormalize some aspects of differentiated function of en-
erocytes such as glucose transport,4 as well as inducing
OCS-2 as shown here.
Intriguingly, in Caco-2 cells, forced SOCS-2 overex-
ression enhanced expression of markers of enterocyte
ifferentiation, sucrase, and alkaline phosphatase. This is
onsistent with enhanced sucrase activity in GH trans-
enic mice2 but not IGF-I transgenic mice.1 A recent
eport indicates that GH induction of SOCS-2 plays a
ole in differentiation of neurons from progenitors within
he brain.56 This, together with our current findings in
ntestinal epithelial cells, suggests that SOCS-2 may
ave a key role in dictating the balance between prolif-
ration and differentiation of multiple cell types.
At present, the mechanisms by which SOCS-2 atten-
ates proliferation of intestinal epithelial cells and pro-
otes differentiation are not defined. In other systems, it
s well established that SOCS limit STAT activation by
ytokines.10 In Caco-2 cells, proliferation is known to be
ssociated with high-level STAT-3 activation and con-
uence and differentiation with reduced STAT-3 activa-
ion.57 It is therefore tempting to speculate that the
ncreases in SOCS-2 expression observed here in conflu-
nt Caco-2 cells mediates STAT-3 inactivation at con-
uence. Forced SOCS-2 overexpression also may induce
ucrase or alkaline phosphatase by inhibiting STAT-3.
uture studies will be required to test this possibility,
ut it is noteworthy that a blast search revealed that the
ucrase-isomaltase promoter contains 7 STAT-like bind-
ng sites within 3000 bases of the transcription start site,
nd several lie in proximity to caudal-type homeobox
Cdx) and GATA binding sites implicated in sucrase
egulation.58,59
SOCS-2 null mice exhibit increases in body weight,
hich is first observed at times associated with rapid
ostnatal increases in growth known to be dependent on
H and IGF-I.16 The body growth phenotype of SOCS-2
ull mice is intermediate between that observed in trans-
enic mice with GH or IGF-I excess, and SOCS-2 null
ice show increased expression of some but not all
H-regulated genes in liver.16 Additionally, a high-
rowth phenotype observed in the high-growth mouse
odel was found to be the result of loss of the SOCS-2
ene.60 These phenotypes support the concept that
OCS-2 expression in vivo normally exerts a suppressive
ffect on growth mediated by the GH–IGF-I axis and are
onsistent with the new in vivo and in vitro data reported
ere, which show a suppressive role of SOCS-2 on epi-
helial cell proliferation and intestinal growth. In
OCS-2 null mice, circulating IGF-I was normal, al-
hough some organs exhibited increases in IGF-I expres-ion.16 Interestingly, this was shown in only a few of a
umber of organs exhibiting overgrowth in the mice.
OCS-2 may therefore inhibit IGF-I induction by GH in
cell- or tissue-specific manner. During TPN, this may
e the case because GH treatment increased serum IGF-I
ut did not elevate local IGF-I expression in the intestine
n the present or previous studies.4,5 Our current findings
how increased weight and length of small intestine and
olon in null mice vs. WT, providing in vivo evidence
hat SOCS-2 normally limits intestinal growth. Colonies
f SOCS-2 null mice are currently being established in
ur laboratory to analyze intestinal phenotype in more
etail, including analysis of enterocyte differentiation
uring development and studies of intestinal responsive-
ess to GH and IGF-I.
Isolated crypts potentially provide very useful systems
o study ex vivo actions of GH and IGF-I in a simple
ulture system with a nontransformed phenotype, which
etains some of the cell contacts and architectural features
f crypts in vivo. Comparisons of SOCS-2 null and WT
rypts here provided evidence for effects of SOCS-2 to
imit the proliferative actions of GH and IGF-I in com-
ination. It was, however, somewhat surprising that
GF-I alone did not have mitogenic actions in the iso-
ated crypt preparations. Variations in isolation and cul-
ure conditions may promote optimal IGF-I responsive-
ess or preservation of IGF-I receptor expression.
ngoing studies are evaluating levels of expression of
GF-I receptor and key signaling molecules under dif-
erent isolation and culture conditions to identify strat-
gies that will maximize the usefulness of this system for
uture studies of GH and IGF-I action and interactions.
In conclusion, these studies show that SOCS-2 is
nduced in response to GH treatment in intestine in vivo
nd in intestinal epithelial cells in vitro. Evidence in 2
ell lines and isolated crypts from SOCS-2 null and WT
ice indicates that SOCS-2 limits epithelial cell prolif-
ration. These data indicate that SOCS-2 mediates or
ontributes to the reduced potency of GH vs. IGF-I as a
ediator of growth of the mucosal epithelium. Indeed,
ur findings in IEC-6 cells and isolated crypts support a
ew mechanism of GH:IGF-I interaction, whereby direct
ctions of GH on epithelial cells are to limit basal
roliferation or mitogenic effects of IGF-I. Our data
uggest that SOCS-2 mediates or is required for these
ffects of GH.
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